Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Raman spectroscopy and colorectal cancer

ABSTRACT: Background and study aims Bowel cancer is one of the commonest cancers worldwide. Earlier detection causes better outcomes for patients and longer survival. Symptoms of bowel cancer are non-specific and are shared by harmless bowel disorders. It is a challenge for doctors in general practice to diagnose bowel cancer and many symptomatic patients are sent to hospital for tests to rule it out. This is normally a colonoscopy, which is expensive, uncomfortable and can be harmful. The current approach to diagnosis causes great anxiety in patients waiting for these tests and is not a prudent approach to diagnosis. To allow earlier diagnosis by GPs we have studied whether a newly designed blood test taken in primary care is accurate and effective in patients with bowel symptoms that could be linked with cancer. This would benefit a large number of patients who are concerned about their bowel symptoms without the need for referral to hospital. It could also lead to diagnosis of bowel cancer at an earlier stage improving survival in the longer term. The aim of this study is to use a newly developed blood test for bowel cancer in primary care to achieve an earlier diagnosis. This would allow more timely appropriate treatment both for patients diagnosed with bowel cancer and those who are cancer free. Who can participate? Adults aged 50 years and older who have symptoms of bowel cancer. What does the study involve? Participants are randomly allocated to one of two groups. Those in the first group have their Raman spectroscopy blood test done immediately and those in the second grou have their sample tested after they’ve had a diagnosis. The amount of participants who are referred on the USC pathway from each group are assessed after 12 months.

DISEASE(S): Colorectal Cancer

PROVIDER: 2416539 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of mucosa from human patients with irritable bowel syndrome or ulcerative colitis

Project description:IBS: Patients who have undergone a diagnostic program for gastrointestinal symptoms and where the diagnosis irritable bowel syndrome was reached. UC: Patients with well-diagnosed ulcerative colitis

2007-10-02 | E-GEOD-2461 | biostudies-arrayexpress

Control (IBS) & Ulcerative colitis (UC) subjects

2005-04-01 | GSE2461 | GEO

Plasma induced signatures reveal an extracellular milieu possessing an immunoregulatory bias in treatment naïve inflammatory bowel disease

Project description:The complex milieu of inflammatory mediators associated with many diseases is often too dilute to directly measure in the periphery, necessitating development of more sensitive measurements suitable for mechanistic studies, earlier diagnosis, guiding selection of therapy, and monitoring interventions. Previously, we determined that plasma of recent-onset (RO) Type 1 diabetes (T1D) patients induce a proinflammatory transcriptional signature in fresh peripheral blood mononuclear cells (PBMC) relative to that of unrelated healthy controls (HC). Here, using an optimized cryopreserved PBMC-based protocol, we apply this approach to inflammatory bowel disease by examining groups of Crohn's disease (CD) and ulcerative colitus (UC) patients. The induced plasma induced signatures are compared to those of Type 1 diabetes patients (RO T1D) as well as unrelated healthy controls (uHC).

2015-10-01 | GSE71730 | GEO

Human urine proteome in overactive bladder syndorme

Project description:The aim of this study is analysis of urinary proteomic pattern in healthy people and patients suffering from OAB symptoms by means of mass spectrophotometry. Establishing characteristic protein profiles, qualitative and quantitative, for OAB will help to define specific protein marker and will allow to develop new investigative protocol enabling to discover at what stage of post-genetic changes urothelium cells change their proteomic profile causing OAB symptoms. Patients will be divided into two groups: group A – OAB patients and group B – control group, without any urinary tract symptoms. All participants will be questionnaired with appropriate tools evaluating quality of life of patients with lower urinary tract symptoms and bladder diary. Urine samples will be taken twice with 7 day gap and then prepared for further evaluation with mass spectrophotometry. Mass spectrophotometry will be performed for all labeled samples with QExactive spectrophotometer. In order to provide maximal credibility and reliability of acquired data each sample will be managed in triplicate. Those result will be analyzed with specific statistical methods and final results will be correlated between the groups. In long-term perspective results of this project will help to understand the underlying pathomechanisms of overactive blabber syndrome. In future those results will be applied for further research in OAB sufferers allowing for precise and objective diagnosis and prognosis. In our opinion it will also serve as a tool for estimations of treatment efficacy of new therapeutic methods. In consequence the project will allow us to create a unique toolkit, combining spectrophotometry, urinary proteomic pattern differences and quality of life correlated with OAB symptoms severity. It will enable to develop new perspectives for overactive bladder pathophysiology research and new therapeutic strategies.

2020-05-12 | PXD017799 | Pride

Chemoproteomics-based discovery of novel biomarkers for high-grade serous ovarian cancer recurrence through a patient-derived xenograft strategy

Project description:High grade serous ovarian carcinoma (HGSC) is the most common and lethal subtype of gynecologic malignancy in women. The current standard of treatment combines cytoreductive surgery and chemotherapy. Despite the efficacy of initial treatment, most patients develop cancer recurrence, and 70% of patients die within 5-years of initial diagnosis. CA125 is the current FDA-approved biomarker used in the clinic to monitor response to treatment and recurrence. Although increasing levels of CA125 precede clinical symptoms of recurrence, often second-look surgeries often reveal microscopic and macroscopic tumors present during remission. Here, we describe a novel strategy for the discovery of serum biomarkers aimed at earlier detection of cancer recurrence. We combined HGSC patient-derived xenograft models, chemoproteomic enrichment of N-glycosylated peptides and systematic development of targeted proteomics assays for rapid biomarker identification and orthogonal verification. The verification of candidates in two independent, longitudinal serum cohorts from HGSC patients (n=96 serum samples) identified four novel biomarker candidates for earlier detection of HGSC recurrence.

2018-08-27 | MSV000082853 | MassIVE

Quantitative label-based canine faecal proteomics

Project description:In small animals, diarrhoea is a regular presentation, the aetiology of which can be varied, from an isolated self-limiting event to more serious episodes requiring symptomatic and supportive treatment. Chronic diarrhoea, defined as diarrhoea lasting longer than 3 weeks, is a relatively common problem often prompting referral for more detailed investigation. Although the potential cause of chronic diarrhoea includes chronic intestinal parasitism and alimentary neoplasia (specifically lymphoma), the majority of these dogs will be diagnosed with idiopathic canine chronic enteropathy (CCE), previously referred to as idiopathic inflammatory bowel disease (IBD). Of those cases diagnosed with CCE, further subdivision based on response to treatment trials leads to a final diagnosis of antibiotic responsive diarrhoea (ARD), food responsive diarrhoea (FRD) or idiopathic inflammatory bowl disease (IBD). The aim of this study was to compare the proteomes of faeces of dogs with chronic enteropathies and a population of healthy dogs, and furthermore to identifying proteins that might be useful in distinguishing FRD from ARD from IBD.

2022-08-29 | PXD017454 | Pride

Blood based gene expression signature for diagnosis of epithelial ovarian cancer

Project description:Objective: The immune system is a key player in fighting cancer. Thus, we seeked to identify a molecular ‘immune response signature’ indicating the presence of epithelial ovarian cancer (EOC) and to combine this with a serum protein biomarker panel to increase the specificity and sensitivity for earlier detection of EOC. Methods: Comparing the expression of 32,000 genes in a leukocytes fraction from 48 EOC patients and 20 controls, three uncorrelated shrunken centroid models were selected, comprised of 7, 14, and 6 genes. A second selection step using RT-qPCR data and significance analysis of microarrays yielded 13 genes which were finally used in 343 samples (90 healthy, 6 cystadenoma, 8 low malignant potential tumor, and 239 EOC patients). Using new 65 controls and 224 EOC patients the abundances of six plasma proteins was determined and used in combination with the expression values from the 13 genes for diagnosis of EOC. Results: Combined diagnostic models using either each five gene expression and plasma protein abundance values or 13 gene expression and six plasma protein abundance values can discriminate controls from patients with EOC with Receiver Operator Characteristics Area Under the Curve values of 0.998 and bootstrap .632+ validated classification errors of 3.1% and 2.8%, respectively. The sensitivities were 97.8% and 95.6%, respectively, at a set specificity of 99.6%. Conclusion: The combination of expression based and plasma protein based biomarkers in one diagnostic model increases the sensitivity and the specificity significantly. Such a diagnostic test may allow earlier diagnosis of epithelial ovarian cancer. The expression of a blood cell fraction from 20 healthy controls and 48 patients with epithelial ovarian cancer was compared.

2011-09-01 | E-GEOD-31682 | biostudies-arrayexpress

Small intestinal mucosal transcriptomics in IBS

Project description:Irritable bowel syndrome (IBS) patients often experience meal associated symptoms. Our objective was to determine small intestinal mechanisms of lipid-induced symptoms and rectal hypersensitivity in IBS based on RNA-seq.

2022-02-28 | GSE166869 | GEO

Gene expression patterns in septic and non-septic shock postsurgical patients

Project description:Nowadays, there is no gold standard of sepsis diagnosis, thus there is a challenge to differentiate between shock septic and non-septic shock following a surgery, since patients with both conditions show similar signs and symptoms. In this sense, to get a quick and accurate diagnosis of septic shock is required to allow an immediate and specific treatment for this condition. In this work, we have evaluated the expression profile by microarray analysis from post-surgical septic shock and non-septic shock patients with the aim of proposing a candidate set genes as gold standard to help in distinguishing both conditions.

2020-08-16 | GSE131761 | GEO

Transcription profile of colon biopsies from normal (NOR) donors, patients, underwent resection for CRC (M-CRC) and patients carriers of mutations predisposed to HNPCC (HNPC)

Project description:The challenge of preventing colorectal cancer (CRC) is the early identification of individuals whose apparently normal colorectal mucosa will develop cancer, because of inherited trait or environmental exposure. We sought to use genome-wide expression profiling of endoscopic biopsies to detect a signature of propensity for cancer. We performed oligonucleotide microarray analysis of normal appearing mucosa of the following cases: healthy individuals, disease-free carriers predisposed to HNPCC (hereditary non-polyposis CRC), disease-free patients who underwent curative large bowel resection for CRC 1 to 15 years earlier and patients with CRC. This profiling is based on the analysis of 4 donors who underwent curative large bowel resection for CRC from 1 to 19 years before (M-CRC samples), 4 disease-free carriers of mutations in the mismatch repair system genes, who are predisposed to develop HNPCC (HNPCC samples) and 4 endoscopy-negative, asymptomatic individuals (NOR samples)

2013-11-30 | E-GEOD-23011 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data